๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers

โœ Scribed by Norihiko Kawamata; Carl W. Miller; H. Phillip Koeffler


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
626 KB
Volume
14
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Cyclin and cyclinโ€dependent kinase (a) complexes play important roles in modulating the cell cycle. The CDK inhibitors (a) inhibit the kinase activities of these complexes and block the cell cycle. The p16/multiple tumor suppressor (MTS) 1/inhibitor of CDK4 (INK4) a/CDKN2 gene, a CDKI, is frequently deleted in a variety of human cancers. Recently another CDKI gene, p15/MTS2/INK4b, was cloned and localized to within 20kb of the p16 gene. Moreover, a third CDKI gene, named __p18/INK4__c and having a high degree of protein homology to p16, has now been cloned. To elucidate the importance of these CDKI genes in nonโ€small cell lung cancers (a), we examined DNAs from 34 NSCLC samples for alterations in these genes by Southern blot and polymerase chain reaction (a) โ€singleโ€strand conformational polymorphism (a) analyses. Matched control normal tissues from the same individuals were also examined. Homozygous deletions of the p15 gene were found in three cases. Furthermore, comparative PCR analysis confirmed these deletions and suggested that one additional case had an abnormality of the p15 gene. Neither rearrangements nor deletions of the p18 gene were detected. By PCRโ€SSCP and direct sequencing of the aberrantly migrating bands, we detected only polymorphic nucleotide substitutions in both the p15 and p18 genes. In summary, the frequency of deletions of the p15 gene was 12% (four of 34 cases), and no point mutations in the p15 gene were detected in the NSCLCs. For the p18 gene, no abnormalities were detected. A previous analysis of these NSCLC samples for p16 gene alterations revealed that the three cases with homozygous deletions of the p15 gene also have homozygous deletions of the p16 gene. ยฉ 1995 Wileyโ€ Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Molecular analysis of the cyclin-depende
โœ Akihiko Gemma; Seiichi Takenoshita; Koichi Hagiwara; Aikou Okamoto; Elisa A. Spi ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 660 KB

Cyclin-dependent kinillre-4 inhibitor genes (INK4) regulate the cell cycle and are candidate tumor-suppressor genes. To determine if alterations in the coding regions of the p18 and p l 9 genes, which are novel members of the INK4 family and if they correlate with the development of human cancer, 10

Intragenic mutations of the p16INK4, p15
โœ Marek R. Rusin; Aikou Okamoto; Mieczyslaw Chorazy; Kazimierz Czyzewski; Jolanta ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 721 KB

The p p ! 6INK4 and p I8 genes are members of the gene famil coding for inhibitors of cyclin-dependent kinases 4 and 6. frequently deleted in many human neoplasms. To examine the role of these 3 genes in lung carcinogenesis, somatic mutations within the genes were analyzed by single-strand conformat

Genetic and epigenetic alterations of th
โœ Rossella Elisei; Masaaki Shiohara; H. Phillip Koeffler; James A. Fagin ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 186 KB ๐Ÿ‘ 2 views

## Background: D-type cyclins, in association with the cyclin-dependent kinases cdk4 and cdk6, promote progression through the g1 phase of the cell cycle. cdk activity is modulated by inhibitors such as p15ink4b and p16ink4a. loss of function of p15ink4b and p16ink4a (multiple tumor suppressor-i an

Increased expression of cyclin-dependent
โœ Ying Dong; Michael D. Walsh; Michael A. McGuckin; Brian B. Gabrielli; Margaret C ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 336 KB ๐Ÿ‘ 2 views

Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16 INK4A (p16). Most benign tumours showed no p16 expression in the tumour